Nurix Therapeutics, Inc. (NRIX) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Nurix Therapeutics, Inc. is facing a significant shift in its reporting landscape as it transitions out of the “smaller reporting company” category by the end of November 2024, due to the increased market value of its common stock. This change will necessitate adherence to more stringent disclosure and reporting requirements starting with the fiscal quarter ending February 2025. The inability to meet these enhanced standards could adversely impact Nurix’s business operations and financial health, underscoring the need for rigorous compliance strategies to manage this evolving risk profile.
The average NRIX stock price target is $30.00, implying 26.96% upside potential.
To learn more about Nurix Therapeutics, Inc.’s risk factors, click here.
